乳腺癌内分泌治疗加时代

激素受体（HR）阳性乳腺癌对内分泌治疗有效但也会产生耐药，以内分泌治疗为基础的联合治疗克服了耐药并提高了内分泌治疗的效果。乳腺癌的治疗已进入内分泌治疗加时代，这包括乳腺癌内分泌治疗联合分子靶向药物、血管生成抑制剂、磷脂酰肌醇-3激酶（PI3K）抑制剂、哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂、细胞周期素依赖激酶（CDK)4/6抑制剂、抗HER2剂和表观遗传调节剂。本文系统总结乳腺癌内分泌联合治疗的临床研究结果和潜在药物。

Endocrine combined therapy of breast cancer

Endocrine therapies that target the hormone receptors-positive breast cancer have substantial activity,yet the development of resistant to therapy is inevitable.The era of endocrine combined therapy of breast cancer has arrived.Combinational therapeutics can overcome resistance and improve clinical benefit.Combinational strategies include adding inhibitors targeting growth factors,angiogenesis,phosphoinositide 3-kinase (PI3K)，mammalian target of rapamycin (mTOR),cyclin-dependent kinase 4/6,human epidermal growth factor receptor 2,or targeted epigenetic agents to endocrine therapy.Herein,we review the current study and new drugs of endocrine combined therapy of breast cancer.